| Abstract Title: |
Mild cognitive impairment and quality of life |
| Authors: |
Camelia Mila, Delia Podea |
| Affiliation: |
Psychiatry Department, “Vasile Goldis” Western University, Arad, Romania |
| Abstract text: |
Background: In older people, mental and physical function decrease due to multiple age related changes, which in turn may affect quality of life .The most obvious decrease in mental function is cognitive decline, specified as Mild Cognitive Impairment (MCI), considered to be a potential transitional stage between normal cognitive function and Alzheimer’s disease. Objective: The aim of this study is to evaluate the improvement of quality of life by improvement of cognition to the patient with MCI treated with nootropics (Piracetamum ) and antioxidants. Material and Methods: The study comprises a number of 40 elderly patients diagnosed with mild cognitive impairment. These patients were divided in two groups: group A that comprises 20 patients diagnosed with mild cognitive impairment that were treated with piracetamum 4 tablets/day (daily dose: 1600 mg); group B that comprises 20elderly patients diagnosed with mild cognitive impairment that were treated with antioxidants: Coenzyme Q10 MMSE score between 28-21 points is considered mild cognitive impairment. The inclusion criteria were: patients with 65 years of age and older than 65 patients with mild cognitive impairment. The exclusion criteria were: patients with mild cognitive impairment due to major depressive disorder and schizophrenia; patients with moderate and severe cognitive impairment. The patients were evaluated with MMSE (Mini Mental State Evaluation) and GAF (Global Assessment of Functioning) at the inclusion and after 6 months of treatment. Results: The average of MMSE in group A was 25.9 and for group B 25.5 The patients treated with nootropics have had a better outcome, cognitive performance improves with 2,6 points for group A and with 1,8 points for group B. Improvement of cognitive performance improve the quality of life of this patients, the GAF Scores improve from 45.4 points to 67.3 at group A and from 44.8 points to 55.3 in group B. |
| Keywords: |
mild cognitive impairment, quality of life, nootropics |
| Presentation type: |
Poster |
| Correspondence: |
no. 17, Octavian Goga St., Arad, Romania |
| Email: |
grcami@yahoo.com |
